Skip to content
10-Q

Quarterly Report

Verrica Pharmaceuticals Inc. VRCA

0000950170-25-070452

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 7, 2025 92.49M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $27.81M
Long Term Debt Q1 2025 · Dec 31, 2024 $30.98M
Current Liabilities Q1 2025 · Mar 31, 2025 $29.4M
Current Liabilities Q1 2025 · Dec 31, 2024 $29.01M
Total Liabilities Q1 2025 · Mar 31, 2025 $60.75M
Total Liabilities Q1 2025 · Dec 31, 2024 $63.99M
Current Assets Q1 2025 · Mar 31, 2025 $39.47M
Current Assets Q1 2025 · Dec 31, 2024 $51.18M
Total Assets Q1 2025 · Mar 31, 2025 $42.18M
Total Assets Q1 2025 · Dec 31, 2024 $54.13M
Cost Of Revenue Q1 2025 · Mar 31, 2025 $700K
Revenue Q1 2025 · Mar 31, 2025 $3.44M
Revenue Q1 2025 · Mar 31, 2024 $3.83M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $46.33M
Stock Issued Q1 2025 · Nov 22, 2024 45.52M sh
Shares Diluted Q1 2025 · Mar 31, 2024 46.48M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$19.95M
Stockholders Equity Q1 2025 · Mar 31, 2024 $1.51M
Stockholders Equity Q1 2025 · Dec 31, 2023 $19.76M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.44
Eps Basic Q1 2025 · Mar 31, 2024 −$0.44
Sga Expense Q1 2025 · Mar 31, 2024 $16.34M
Rd Expense Q1 2025 · Mar 31, 2024 $4.95M
Rd Expense Q1 2025 · Jul 21, 2023 $4.5M
Net Income Q1 2025 · Mar 31, 2024 −$20.33M
Operating Income Q1 2025 · Mar 31, 2024 −$18.6M